Ms. Logan led the company for more than 12 years, and according to Tom D’Alonzo, chairman of Salix’s board of directors, Ms. Logan took “Salix from an early-stage commercial company with a market capitalization of approximately $200 million, one product and less than $25 million in annual revenues, to a leading gastroenterology-focused specialty pharmaceutical company with a multi-billion dollar market capitalization, more than 20 products and over $1 billion in annual revenues.”
Mr. D’Alonzo will be appointed acting CEO. Ms. Logan will remain a consultant to the company.
More articles on GI/endoscopy:
Global endoscopy market to reach $47B by 2020: 8 key trends
GI Dynamics names Michael Dale president & CEO
Diagnostic Endoscopy Center’s Dr. Stuart Waldstreicher honored
